Novel antineoplastic agents

Bibliography

• ECKER G, CHIBA P: Recent developments in overcoming tumour cell multi drug resistance. Exp. Opin. Ther. Pat-ents (1997) 7:589–599.
   Web of Science ®Google Scholar
• RAK J, KERBEL RS: Treating cancer by inhibiting angio-genesis: new hopes and potential pitfalls. Cancer Metast. Rev. (1996) 15:231–236.
   PubMedGoogle Scholar
• HEAVNER GA: Active sequences in cell adhesion mole-cules: targets for therapeutic intervention. Drug Discov. Today (1996) 1:295–304.
   Web of Science ®Google Scholar
• VOEST EE: Inhibitors of angiogenesis in a clinical per-spective. Anti-Cancer Drugs (1996) 7:723–727.
   PubMed Web of Science ®Google Scholar
• YU AE, HEWITT RE, CONNOR EW, STETLER STEVENSON WG: Matrix metalloproteinases: novel targets for di-rected cancer therapy. Drugs Aging (1997) 11:229–244.
   PubMed Web of Science ®Google Scholar
• GASTL G, HERMANN T, STEURER M et al.: Angiogenesis as a target for tumor treatment. Oncology (1997) 54:177–184.
   PubMed Web of Science ®Google Scholar
• BECKETT RP: Recent advances in the field of matrix met-alloproteinase inhibitors. Exp. Opin. Ther. Patents (1996) 6:1305–1315.
   Google Scholar
• CAPONIGRO F, FRENCH RC, KAYE SB: Protein kinase C: a worthwhile target for anticancer drugs. Anti-Cancer Drugs (1997) 8:26–33.
   PubMed Web of Science ®Google Scholar
• GRANTS, JARVIS WD: Modulation of drug induced apop-tosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy. Clin. Cancer Res. (1996) 2:1915–1920.
   PubMedGoogle Scholar
• PATRICK DR, HEIMBROOK DC: Protein kinase inhibitorsfor the treatment of cancer. Drug Discov. Today (1996) 1:325–330.
   Google Scholar
• RIFKIND RA, RICHON VM, MARKS PA: Induced differen-tiation, the cell cycle, and the treatment of cancer. Phar-macol. Ther. (1996) 69:97–102.
   PubMed Web of Science ®Google Scholar
• SCHELLENS JHM, PRONK LC, VERWEIJ J: Emerging drug treatments for solid tumours. Drugs (1996) 51:45–72.
   PubMedGoogle Scholar
• LEVITZKI A, GAZIT A: Tyrosine kinase inhibition: an ap-proach to drug development. Science (1995) 267:1782–1788.
   PubMed Web of Science ®Google Scholar
• LANGDON SP, SMYTH JF: Inhibition of cell signalling pathways. Cancer Treat. Rev. (1995) 21:65–89.
   PubMedGoogle Scholar
• BOUTIN JA: Tyrosine protein kinase inhibition and can-cer. Intern.j Biochem. (1994) 26:1203–1226.
   PubMedGoogle Scholar
• REPHAELI A, NORDENBERG J: Cytodifferentiation induc-ers as anticancer agents. Oncol. Rep. (1994) 1:481–487.
   PubMedGoogle Scholar
• SEBTI SM, HAMILTON AD: Inhibition of ras prenylation: a novel approach to cancer chemotherapy. Pharmacol. Ther. (1997) 74:103–114.
   PubMed Web of Science ®Google Scholar
• PERRIN D, HALAZY S, HILL B: Inhibitors of ras farnesyla-tion: tomorrow's anticancer agents. Bull. Cancer (1997) 84:635–642.
   PubMedGoogle Scholar
• LERNER EC, HAMILTON AD, SEBTI SM: Inhibition of ras prenylation: a signaling target for novel anti cancer drug design. Anti-Cancer Drug Des. (1997) 12:229–238.
   PubMedGoogle Scholar
• LEVY R: Farnesyl transferase inhibitors (anti ras): a new class of anti cancer drugs. Presse Med. (1995) 24: 725–729.
   PubMedGoogle Scholar
• GIBBS JB, OLIFF A: The potential of farnesyltransferaseinhibitors as cancer chemotherapeutics. Ann. Rev. Phar-macol. Toxicol (1997) 37:143–166.
   PubMed Web of Science ®Google Scholar
• KELLOFF GJ, LUBET RA, FAY JR et al.: Farnesyl proteintransferase inhibitors as potential cancer chemopre-ventives. Cancer Epidem. Biomark. Prevent. (1997) 6:267–282.
   PubMed Web of Science ®Google Scholar
• UNGER C: Current concepts of treatment in medical on-cology: new anticancer drugs. J. Cancer Res. Clin. Oncol. (1996) 122:189–198.
   PubMed Web of Science ®Google Scholar
• HIWASA T: Ras inhibitors. Oncol. Rep. (1996) 3:7–14.
   PubMed Web of Science ®Google Scholar
• PARK HW, BODULURI SR, MOOMAW JF, CASEY PJ, BEESE LS: Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution. Science (1997) 275:1800–1804.
   Google Scholar
• GRAHAM SL, WILLIAMS TM: Inhibitors of protein fame-sylation. Exp. Opin. Ther. Patents (1996) 6:1295–1304.
   Web of Science ®Google Scholar
• TRAXLER PM: Protein tyrosine kinase inhibitors in can-cer treatment. Exp. Opin. Ther. Patents (1997) 7:571–588.
   Web of Science ®Google Scholar
• KELLAND LR: New platinum antitumor complexes. Crit. Rev. Oncol. Hematol (1993) 15:191–219.
   PubMed Web of Science ®Google Scholar
• HAMILTON TC, O'DWYER PJ, OZOLS RF: Platinum ana-logues in preclinical and clinical development. Curr. Opin. Oncol (1993) 5:1010–1016.
   PubMedGoogle Scholar
• CHRISTIAN MC: The current status of new platinum ana-logs. Semin. Oncol. (1992) 19:720–733.
   PubMed Web of Science ®Google Scholar
• BELANI CP, VAN ECHO DA, AISNER J: Platinum com-pounds. Curr. Opin. Oncol. (1989) 1:186–191.
   PubMedGoogle Scholar
• ZWELLING LA: Cisplatin and new platinum analogs. Cancer Chemother. Biol. Response Modif (1988) 10:64–72.
   PubMedGoogle Scholar
• MCKEAGE MJ: Comparative adverse effect profiles of platinum drugs. Drug Safety. (1995) 13:228–244.
   PubMed Web of Science ®Google Scholar
• KOPF MAIER P: Complexes of metals other than plati-num as antitumour agents. Eur. J. Clin. Pharmacol (1994) 47:1–16.
   PubMedGoogle Scholar
• NICOLAOU KC, DAI WM, TSAY SC, ESTEVEZ VA, WRASI-DLO W: Designed enediynes: a new class of DNA-cleaving molecules with potent and selective antican-cer activity. Science (1992) 22:1172–1178.
   Google Scholar
• NICOLAOU KC, STABILA P, ESMAELI AZAD B, WRASIDLOW, HIATT A: Cell-specific regulation of apoptosis by de-signed enediynes. Proc. Natl. Acad. Sci. USA (1993) 15:3142–3146.
   Google Scholar
• NICOLAOU KC, SMITH AL, YUE EW: Chemistry and biol-ogy of natural and designed enediynes. Proc. Natl. Acad. Sci. USA (1993) 90:5881–5888.
   PubMedGoogle Scholar
• WRASIDLO W, HIATT A, MAUCH S, MERLOCK RA, NICO-LAOU KC: In vivo efficacy of novel synthetic enediynes. Acta Oncol (1995) 34:157–164.
   PubMed Web of Science ®Google Scholar
• BATTIGELLO JM, CUI M, ROSHONG S, CARTER BJ:Enediyne-mediated cleavage of RNA. Bioorg. Med. Chem. (1995) 3:839–849.
   PubMedGoogle Scholar
• SMITH AL, NICOLAOU KC: The enediyne antibiotics. J.Med. Chem. (1996) 39:2103–2117.
   PubMed Web of Science ®Google Scholar
• NITISS JL, WANG JC: Mechanisms of cell killing by drugsthat trap covalent complexes between DNA topoi-somerases and DNA. Mol. Pharmacol (1996) 50:1095–1102.
   PubMed Web of Science ®Google Scholar
• ROCA J: The mechanisms of DNA topoisomerases. Trends Biochem. Sci. (1995) 20:156–160.
   PubMed Web of Science ®Google Scholar
• GUPTA M, FUJIMORI A, POMMIER Y: Eukaryotic DNA to-poisomerases I. Biochim. Biophys. Acta Gene Struct. Exp. (1995) 126:1–14.
   Google Scholar
• RIVORY LP, ROBERT J: Pharmacology of camptothecin and its derivatives. Bull. Cancer (1995) 82:265–285.
   PubMedGoogle Scholar
• RIVORY LP, ROBERT J: Molecular, cellular, and clinical aspects of the pharmacology of 20(s)camptothecin and its derivatives. Pharmacol. Ther. (1995) 68:269–296.
   PubMed Web of Science ®Google Scholar
• BINASCHI M, ZUNINO F, CAPRANICO G: Mechanism ofaction of DNA topoisomerase inhibitors. Stem Cells (1995) 13:369–379.
   PubMed Web of Science ®Google Scholar
• WANG HK, MORRISNATSCHKE SL, LEE KH: Recent ad-vances in the discovery and development of topoi-somerase inhibitors as antitumor agents. Med. Res. Rev. (1997) 17:367–425.
   PubMed Web of Science ®Google Scholar
• CAPRANICO G, BINASCHI M, BORGNETTO ME, ZUNINO F,PALUMBO M: A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poi-sons. Trends Pharm. Sci. (1997) 18:323–329.
   PubMed Web of Science ®Google Scholar
• BERGER JM, WANG JC: Recent developments in DNA to-poisomerase II structure and mechanism. Curr. Opin. Struct. Biol. (1996) 6:84–90.
   PubMed Web of Science ®Google Scholar
• BERGER JM, GAMBLIN SJ, HARRISON SC, WANG JC: Struc-ture and mechanism of DNA topoisomerase II. Nature (1996) 379:225–232.
   PubMed Web of Science ®Google Scholar
• NOWAK D, DRZEWOSKI J: Anthracycline induced oxida-tive stress: its role in the development of cardiac dam-age. Cancer J. (1996) 9:296–303.
   Google Scholar
• MAZUE G, IATROPOULOS M, IMONDI A et al.: Anthracy-clines: a review of general and special toxicity studies. Int. J. Oncol (1995) 7:713–726.
   PubMedGoogle Scholar
• BOGER DL, JOHNSON DS: CC-1065 and the duo-carmycins: unraveling the keys to a new class of natu-rally derived DNA alkylating agents. Proc. Natl. Acad. Sci. USA (1995) 92:3642–3649.
   PubMed Web of Science ®Google Scholar
• CHU E, JOHNSTON PG, GREM JL et al: Antimetabolites. Cancer Chemother. Biol. Response Modif (1994) 15: 1–31.
   PubMedGoogle Scholar
• RUSTUM YM, HARSTRICK A, CAO S et al.: Thymidylate synthase inhibitors in cancer therapy: direct and indi-rect inhibitors. J. Clin. Oncol (1997) 15:389–400.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ G: Fludarabine phosphate. A new antican-cer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma. Invest. New Drugs (1994) 12:75–92.
   Google Scholar
• HUIZING MT, MISSER VHS, PIETERS RC et al.: Taxanes: anew class of antitumor agents. Cancer Invest. (1995) 13:381–404.
   PubMed Web of Science ®Google Scholar
• NICOLAOU KC, GUY RK: The conquest of taxol. Angew. Chem. Intern. Ed. (1995) 34:2079–2090.
   Google Scholar
• ROWINSKY EK, DONEHOWER RC: Drug therapy: pacli-taxel ffaxofi. New Engl. J. Med. (1995) 332:1004–1014.
   PubMed Web of Science ®Google Scholar
• HAJEK R, VORLICEK J, SLAVIK M: Paclitaxel (Tama a re-view of its antitumor activity in clinical studies. Neo-plasma (1996) 43:141–154.
   Google Scholar
• KATAYAMA H, KAWADA Y, OSHIYAMA T, EJIMA A: Syn-thetic dual inhibitors of DNA topoisomerase I and II. Chem. Pharm. Bull. (1996) 44:1276–1278.
   Google Scholar
• CUMMINGS J, MACPHERSON JS, MEIKLE I, SMYTH JF: De-velopment of anthracenyl amino acid conjugates as to-poisomerase I and II inhibitors that circumvent drug resistance. Biochem. Pharmacol (1996) 52:979–990.
   PubMed Web of Science ®Google Scholar
• LETEURTRE F, FUJIMORI A, TANIZAWA A et al.: Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions. J. Biol. Chem. (1994) 269:28702–28707.
   PubMedGoogle Scholar
• PODDEVIN B, RIOU JF, LAVELLE F, POMMIER Y: Dual to-poisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Mol Pharmacol. (1993) 44:767–774.
   PubMed Web of Science ®Google Scholar
• SHAY JW, WRIGHT WE: Telomerase activity in human cancer. Curr. Opin. Oncol. (1996) 8:66–71.
   PubMedGoogle Scholar
• HAMILTON SE, COREY DR: Telomerase: anti-cancer tar-get or just a fascinating enzyme? Chem. Biol (1996) 3:863–867.
   Google Scholar
• RAYMOND E, SUN D, CHEN SF, WINDLE B, VON HOFF DD: Agents that target telomerase and telomeres. Curr. Opin. Biotechnol (1996) 7:583–591.
   PubMed Web of Science ®Google Scholar
• DARZYNKIEWICZ Z: Apoptosis in antitumor strategies: modulation of cell cycle or differentiation. J. Cell Bio-chem. (1995) 58:151–159.
   PubMed Web of Science ®Google Scholar
• HICKMAN JA, POTTEN CS, MERRITT AJ, FISHER TC: Apop-tosis and cancer chemotherapy. Philos. Trans. Royal Soc. fond. Br. Biol. Sci. (1994) 345:319–325.
   PubMed Web of Science ®Google Scholar
• MARTIN SJ, GREEN DR: Apoptosis as a goal of cancertherapy. Curr. Opin. Oncol (1994) 6:616–621.
   PubMedGoogle Scholar
• FISHER DE : Apoptosis in cancer therapy: crossing the threshold. Cell (1994) 78:539–542.
   PubMed Web of Science ®Google Scholar
• SMETS LA: Programmed cell death (apoptosis) and re-sponse to anti-cancer drugs. Anti-Cancer Drugs (1994) 5:3–9.
   PubMed Web of Science ®Google Scholar
• ROTH JA, CRISTIANO RJ: Gene therapy for cancer: what have we done and where are we going. J. Natl. Cancer Inst. (1997) 89:21–39.
   PubMed Web of Science ®Google Scholar
• DORNBURG R: From the natural evolution to the genetic manipulation of the host range of retroviruses. Chem. (1997) 378:457–468.
   Google Scholar
• SCOTT RE: Differentiation, differentiation/gene ther-apy and cancer. Pharmacol. Ther. (1997) 73:51–65.
   PubMedGoogle Scholar
• MILLER N, WHELAN J: Progress in transcriptionally tar-geted and regulatable vectors for genetic therapy. Hu-man Gene Ther. (1997) 8:803–815.
   PubMed Web of Science ®Google Scholar
• LICHT T, HERRMANN F, GOTTESMAN MM, PASTAN I: In vivo drug selectable genes: a new concept in gene ther-apy. Stem Cells (1997) 15:104–111.
   PubMedGoogle Scholar
• ROSENTHAL FM, MERTELSMANN R: Present strategies for gene therapy in cancer. Onkologie (1997) 20:26–34.
   Google Scholar
• BILBAO G, CURIEL DT: Gene therapy for cancer thera-peutics. Exp. Opin. Ther. Patents (1996) 6:1267–1284.
   Web of Science ®Google Scholar